Sep 5, 2017
Edwin Klumper - new CEO in Lytix Biopharma

Lytix Biopharma AS today announces that the Board of Directors has appointed Edwin Klumper MD, PhD, MBA as the new CEO effective as of today replacing Håkan Wickholm, who reassumes his previous role as Chief Business Officer.


Gert Wilhelm Munthe, the Chairman of Lytix Biopharma AS says:

“On behalf of the Board, I would like to thank Håkan for taking on the role as acting CEO in March 2016. Håkan has led the company in an excellent way, and it is important for the company that he now can focus all his efforts on business development.”


Dr. Klumper is a Dutchman who brings 25 years of relevant experience in the international pharmaceutical and biotech industry with an expertise in clinical oncology drug development. Prior positions includes CEO for SMS-oncology, acting CMO at several biotech companies, VP marketing & sales Europe at Nabi Biopharmaceuticals and brand director at Amgen Europe. Dr. Klumper has founded two private companies, launched a block buster drug in Europe and has been an advisor for more than 50 cancer drug development programs.


Munthe adds:

 “We are now in a very important stage of the company and the Board felt it was time to further strengthen the management team to develop Lytix Biopharma and its lead product LTX-315. We are delighted to announce the appointment of Dr. Edwin Klumper. He has a highly relevant background in cancer research, drug development and clinical trials, combining a strong scientific and business background with previous leadership roles. Edwin will be responsible for driving the development of Lytix Biopharma and our innovative therapies to cancer patients. His result-oriented approach and ability to think strategically makes the board confident that he will lead Lytix through important milestones and create a profitable business for Lytix Biopharma’s shareholders.”


Dr. Edwin Klumper concludes:

“My goal is to take Lytix Biopharma to the next level from a regional biotech spin-off to a globally recognized immuno-oncology biotech by turning its science into business.”